Form 4: Precigen Executive Donald P. Lehr Reports Stock Transactions Following PSU Vesting

Precigen's Chief Legal Officer, Donald P. Lehr, acquired 54,000 shares of common stock upon vesting of performance stock units and sold 20,844 shares to cover tax obligations.

Summary

• Donald P. Lehr, Chief Legal Officer of Precigen, Inc., reported transactions involving the company's common stock.
• On January 29, 2025, Mr. Lehr acquired 54,000 shares of common stock as part of the settlement of performance stock units (PSUs) that vested.
• These PSUs were originally granted on August 28, 2024, and vested upon the achievement of certain performance conditions.
• Also on January 29, 2025, 20,844 shares were withheld by Precigen to cover income tax obligations related to the PSU settlement.
• The price of the shares withheld for tax purposes was $1.3 per share.
• Following these transactions, Mr. Lehr beneficially owns 571,282 shares of Precigen common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation. While the vesting of PSUs is positive, the subsequent sale for tax purposes is neutral. Overall, the sentiment is slightly positive but not significantly impactful.

Positives

• The vesting of performance stock units indicates that performance goals were met, which is a positive sign for the company.
• The acquisition of 54,000 shares by a key executive demonstrates confidence in the company's future.

Negatives

• The sale of 20,844 shares, while for tax purposes, could be perceived negatively by some investors.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, potentially leading to short-term price volatility.
• The need to sell shares to cover tax obligations could indicate a lack of other liquid assets for the executive.

Industry Context

This type of transaction is common for executives who receive stock-based compensation. It is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Stock-based compensation is a standard practice across the biotechnology industry, with performance-based vesting being a common mechanism.
• Similar transactions are regularly reported by executives at comparable companies such as Intellia Therapeutics and CRISPR Therapeutics, where stock awards are a significant part of compensation packages.
• The tax withholding process is also standard, with companies often withholding shares to cover the tax liabilities of their employees.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign of the company's performance.
• The sale of shares for tax purposes is unlikely to have a significant impact on stakeholders.

Key Dates

Keywords

Precigen, stock transaction, performance stock units, PSU, insider trading, executive compensation, Donald P. Lehr, SEC Form 4